阿片类药物减量或突然停药与剂量不变对稳定长期阿片治疗患者阿片过量或自杀的比较有效性
该研究采用试验模拟的比较有效性设计,利用2010年1月1日至2018年12月31日美国商业保险或Medicare Advantage理赔数据,纳入年龄≥18岁、接受稳定长期阿片治疗且无阿片滥用证据的个体。比较稳定剂量、减量(剂量降低≥15%)或突然停药三种策略,主要终点为11个月随访内阿片过量或自杀事件。调整后11个月累积发生率:稳定剂量0.96%(95%CI 0.92%-0.99%),减量1.10%(95%CI 0.99%-1.22%),突然停药1.28%(95%CI 0.93%-1.38%);减量与稳定剂量的风险差为0.15%(95%CI 0.03%-0.26%),突然停药与稳定剂量的风险差为0.33%(95%CI -0.03%至0.74%)。作者认为这些结果不支持对无阿片滥用证据的稳定长期阿片剂量个体实施强制减量政策能通过自杀和过量减少短期伤害。
要点
- 在无阿片滥用证据的稳定长期阿片治疗患者中,减量(剂量降低≥15%)11个月阿片过量或自杀调整累积发生率为1.10%(95%CI 0.99%-1.22%),稳定剂量为0.96%(95%CI 0.92%-0.99%)。
- 减量与稳定剂量的风险差为0.15%(95%CI 0.03%-0.26%)。
- 突然停药11个月调整累积发生率为1.28%(95%CI 0.93%-1.38%),与稳定剂量的风险差为0.33%(95%CI -0.03%至0.74%)。
- 按方案分析与意向性治疗分析结果相似。
- 作者认为结果不支持对无阿片滥用证据的稳定长期阿片剂量个体实施强制减量政策能减少短期自杀和过量伤害。
适用人群与场景
- 年龄≥18岁、接受稳定长期阿片治疗且无阿片滥用证据的个体,数据来自2010年1月1日至2018年12月31日美国商业保险或Medicare Advantage理赔数据集。
- 共199 836人(45.1%男性;平均[SD]年龄56.9[12.4]岁;57.6%年龄45-64岁),415 123次符合条件的长期阿片治疗发作。
处置流程与药物剂量
- 三种阿片剂量策略:稳定剂量、减量(剂量降低≥15%)或突然停药。
研究设计与关键结果
- 研究类型为采用试验模拟方法的比较有效性研究,使用美国大型理赔数据集,纳入199 836人、415 123次长期阿片治疗发作;87.1%发作被认为稳定,11.1%被认为减量,1.8%被认为突然停药。
- 主要终点为11个月随访内阿片过量或自杀事件;采用逆概率加权调整基线混杂,主要分析为意向性治疗分析,另进行按方案分析(对不遵守指定治疗者删失)。
- 调整后11个月阿片过量或自杀累积发生率:稳定剂量0.96%(95%CI 0.92%-0.99%),减量1.10%(95%CI 0.99%-1.22%),突然停药1.28%(95%CI 0.93%-1.38%)。
- 减量与稳定剂量的风险差为0.15%(95%CI 0.03%-0.26%);突然停药与稳定剂量的风险差为0.33%(95%CI -0.03%至0.74%)。
- 按方案分析结果与意向性治疗分析相似。
证据类型、等级与局限
- 证据类型:采用试验模拟方法的比较有效性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些结果不支持对接受稳定长期阿片剂量且无阿片滥用证据的个体实施强制减量政策能通过自杀和过量减少短期伤害。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Opioid dosage tapering has emerged as a strategy to reduce harms associated with long-term opioid therapy; however, evidence supporting this approach is limited.
OBJECTIVE: To identify the association of opioid tapering or abrupt discontinuation with opioid overdose and suicide events among patients receiving stable long-term opioid therapy without evidence of opioid misuse.
DESIGN, SETTING, AND PARTICIPANTS: This comparative effectiveness study with a trial emulation approach used a large US claims data set of individuals with commercial insurance or Medicare Advantage who were aged 18 years or older and receiving stable long-term opioid therapy without evidence of opioid misuse between January 1, 2010, and December 31, 2018. Statistical analysis was performed from January 17, 2020, through November 12, 2021.
INTERVENTIONS: Three opioid dosage strategies: stable dosage, tapering (dosage reduction ≥15%), or abrupt discontinuation.
MAIN OUTCOMES AND MEASURES: Time to opioid overdose or suicide event identified from International Classification of Diseases, Ninth Revision and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision diagnosis codes in medical claims over 11 months of follow-up. Inverse probability weighting was used to adjust for baseline confounders. The primary analysis used an intention-to-treat approach; follow-up after assignment regardless of changes in opioid dose was included. A per-protocol analysis was also conducted, in which episodes were censored for lack of adherence to assigned treatment.
RESULTS: A cohort of 199 836 individuals (45.1% men; mean [SD] age, 56.9 [12.4] years; and 57.6% aged 45-64 years) had 415 123 qualifying, long-term opioid therapy episodes; 87.1% of episodes were considered stable, 11.1% were considered a taper, and 1.8% were considered abrupt discontinuation. The adjusted cumulative incidence of opioid overdose or suicide events 11 months after baseline was 0.96% (95% CI, 0.92%-0.99%) with a stable dosage strategy, 1.10% (95% CI, 0.99%-1.22%) with a tapered dosage strategy, and 1.28% (95% CI, 0.93%-1.38%) with an abrupt discontinuation strategy. The risk difference between a taper and a stable dosage was 0.15% (95% CI, 0.03%-0.26%), and the risk difference between abrupt discontinuation and a stable dosage was 0.33% (95% CI, -0.03% to 0.74%). Results were similar using the per-protocol approach.
CONCLUSIONS AND RELEVANCE: This study identified a small absolute increase in risk of harms associated with opioid tapering compared with a stable opioid dosage. These results do not suggest that policies of mandatory dosage tapering for individuals receiving a stable long-term opioid dosage without evidence of opioid misuse will reduce short-term harm via suicide and overdose.
参考来源
- Larochelle MR, Lodi S, Yan S, et al. Comparative Effectiveness of Opioid Tapering or Abrupt Discontinuation vs No Dosage Change for Opioid Overdose or Suicide for Patients Receiving Stable Long-term Opioid Therapy. JAMA Netw Open. 2022. PMID: 35960518. doi:10.1001/jamanetworkopen.2022.26523
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。